MétaCan
Menu
Back to cohort
Record W1567696265 · doi:10.1002/cncr.25998

Reply to treatment of pituitary neoplasms with temozolomide

2011· article· en· W1567696265 on OpenAlexaff
Luis V. Syro, Kálmán Kovács, Bernd W. Scheithauer

Bibliographic record

VenueCancer · 2011
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsSt. Michael's Hospital
Fundersnot available
KeywordsTemozolomideImmunostainingMedicineImmunohistochemistryPituitary tumorsPathologyMethyltransferaseOncologyCancer researchGlioblastomaInternal medicineBiology

Abstract

fetched live from OpenAlex

We appreciate the comments of Dr. Marucci regarding our paper entitled, “Treatment of Pituitary Neoplasms With Temozolomide: A Review”.1 The 6 patients with carcinomas who responded to treatment were the reported patients in the literature. MGMT immunoexpression was only available in 3 of them, and it was negative.1 The 57% of carcinomas that demonstrated low MGMT immunoexpression were from a retrospective study of paraffin-embedded tissues.2 Dr. Marucci raises an important question, can MGMT immunostaining predict response to temozolomide therapy? At present, this is controversial. Several, but not all, publications conclude that MGMT immunoreactivity is a reliable indicator of therapeutic response to temozolomide in patients with pituitary adenomas. With respect to the use of immunohistochemistry, 2 important problems must be addressed, the method and its interpretation. If tissue fixation, processing, and immunostaining are properly performed, then the immunohistochemical findings are reliable. This has been proven by several authors. Obviously, when methods are suboptimally applied, the results are not acceptable. The dispute is not with the method but with its interpretation. In some tumors, every neoplastic cell is MGMT- immunonegative, whereas in others every cell is immunopositive. The former tumors appear to respond to temozolomide, whereas the latter tumors do not. The challenge is that many pituitary tumors consist of a mixture of MGMT-immunonegative and -immunopositive cells. How should such results be interpreted? Maybe the MGMT-immunonegative cell would respond, whereas the immunopositive cells would be resistant? Can immunonegative cells transform to immunopositive cells or vice versa? Is it possible that temozolomide administration depletes MGMT causing transformation of immunopositive cells to immunonegative cells resulting in a beneficial response to temozolomide? Other genetic and/or epigenetic factors may also exist that could affect temozolomide responsiveness. Lastly, Dr. Marucci alludes to the demonstration of promoter methylation and its greater accuracy in predicting a therapeutic response. In published studies and in our experience, perfect correlation between MGMT staining and methylation status has not been achieved. Clearly, all available methods of assessing likelihood of temozolomide response should be used. We feel strongly that MGMT immunoreactivity is valuable and should be pursued. Obviously, more work is needed to address these issues.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.030
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.022
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.030
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.001
Science and technology studies0.0020.003
Scholarly communication0.0020.005
Open science0.0030.001
Research integrity0.0220.029
Insufficient payload (model declined to judge)0.0020.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.280
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueCancerSame topicGlioma Diagnosis and TreatmentFrench-language works237,207